Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Dynavax DVAX -- Ignore unavailable to you. Want to Upgrade?

To: Steve Lokness who wrote (47)	11/1/2007 10:31:37 AM
From: Steve Lokness	Respond to of 184

More news indeed; biz.yahoo.com Dynavax, Merck Partner on Heplisav Thursday November 1, 8:29 am ET Dynavax Technologies, Merck Collaborating to Develop Hepatitis B Vaccine Heplisav NEW YORK (AP) -- Dynavax Technologies Corp. and Merck & Co. Inc. said Thursday they are partnering to develop the late-stage hepatitis B vaccine candidate Heplisav. The drug is currently being studied in a Phase III clinical trial involving adults and patients on dialysis. Merck receives worldwide exclusive rights to Heplisav, will fund future vaccine development and will be responsible for commercialization. It will pay Dynavax $31.5 million and the company will be eligible to receive up to $105 million in development and sales milestone payments. There will also be double-digit tiered royalties on global sales. Dynavax will continue to manage the late-stage studies in Canada and Europe and will be responsible for making the hepatitis B surface antigen component of the vaccine for Merck. Steve